{"id":170159,"date":"2025-09-26T10:26:09","date_gmt":"2025-09-26T10:26:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/170159\/"},"modified":"2025-09-26T10:26:09","modified_gmt":"2025-09-26T10:26:09","slug":"tga-approves-lecanemab-for-alzheimers-treatment","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/170159\/","title":{"rendered":"TGA approves lecanemab for Alzheimer\u2019s treatment"},"content":{"rendered":"<p>&#13;<br \/>\n    News<\/p>\n<p class=\"h6 pt-4 pb-2\">&#13;<br \/>\n            The drug, which is sold as LEQEMBI, has been given the green light by the TGA after an initial rejection last year.&#13;\n        <\/p>\n<p>&#13;<br \/>\n    <img decoding=\"async\" alt=\"Older woman with Alzheimer's\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/09\/1758882369_907_attachment.aspx.jpeg\" \/>&#13;<br \/>\n    &#13;<br \/>\n        There are now more options for the treatment of mild Alzheimer\u2019s disease in Australia.&#13;<br \/>\n    &#13;<\/p>\n<p>&#13;<br \/>\n    A further treatment for mild Alzheimer\u2019s disease has been given regulatory approval, the Therapeutic Goods Administration (TGA) <a href=\"https:\/\/www.tga.gov.au\/news\/news\/tga-approves-registration-lecanemab-leqembi\" rel=\"nofollow noopener\" target=\"_blank\">announced this week<\/a>.\u00a0<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nLecanemab, which is sold as LEQEMBI, is now indicated in adult patients with a diagnosis of mild cognitive impairment and mild dementia due to Alzheimer\u2019s disease.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nIt joins a rapidly emerging area of medications following the TGA\u2019s registration of Donanemab (sold as Kisunla) <a href=\"https:\/\/www.tga.gov.au\/resources\/artg\/420194\" rel=\"nofollow noopener\" target=\"_blank\">in May <\/a>this year, the\u00a0first new treatment for early Alzheimer\u2019s in Australia in 25 years.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nDementia Australia CEO Professor Tanya Buchanan welcomed the TGA\u2019s announcement.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\n\u2018This, along with the approval of Kisunla by the TGA earlier this year and the many other treatments currently being developed, heralds a new and exciting era for the treatment of dementia,\u2019 Professor Buchanan said.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\n\u2018It is important to note that lecanemab does come with possible side effects that need to be carefully communicated to patients so they can make an informed choice, and the treatment needs to be monitored by health professionals.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\n\u2018We also need to ensure people understand that lecanemab is not a cure and is only suitable for people in the early stages of Alzheimer\u2019s disease which is why it is so important for people to receive a timely diagnosis.\u2019<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nLecanemab <a href=\"https:\/\/www1.racgp.org.au\/newsgp\/clinical\/tga-rejects-alzheimer-s-medication-due-to-safety-c\" rel=\"nofollow noopener\" target=\"_blank\">was rejected by the TGA last year<\/a> due to safety concerns. Additional submissions received during the review process from the medication\u2019s sponsor Eisai Aust \u2018satisfactorily addressed the outstanding concerns\u2019, according to the TGA.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nThe medication is an amyloid-lowering therapy in adult patients. The TGA said beta amyloid evidence consistent with Alzheimer\u2019s disease should be confirmed before treatment begins.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nRevised figures released by the Australian Institute of Health and Welfare this month indicate that dementia is now the <a href=\"https:\/\/www1.racgp.org.au\/newsgp\/clinical\/dementia-becomes-nation-s-leading-cause-of-death\" rel=\"nofollow noopener\" target=\"_blank\">leading cause of death among Australians<\/a>.<br \/>&#13;<br \/>\n\u00a0<br \/>&#13;<br \/>\nLog in below to join the conversation.&#13;\n<\/p>\n<p>&#13;<br \/>\n    <a href=\"https:\/\/www1.racgp.org.au\/newsgp\/allnews?tagname=dementia\" class=\"bdg bdg-pr bdg-lg mb-1 text-white\" rel=\"nofollow noopener\" target=\"_blank\">dementia<\/a> <a href=\"https:\/\/www1.racgp.org.au\/newsgp\/allnews?tagname=lecanemab\" class=\"bdg bdg-pr bdg-lg mb-1 text-white\" rel=\"nofollow noopener\" target=\"_blank\">lecanemab<\/a> <a href=\"https:\/\/www1.racgp.org.au\/newsgp\/allnews?tagname=LEQEMBI\" class=\"bdg bdg-pr bdg-lg mb-1 text-white\" rel=\"nofollow noopener\" target=\"_blank\">LEQEMBI<\/a> <a href=\"https:\/\/www1.racgp.org.au\/newsgp\/allnews?tagname=medication\" class=\"bdg bdg-pr bdg-lg mb-1 text-white\" rel=\"nofollow noopener\" target=\"_blank\">medication<\/a> &#13;\n<\/p>\n<p>    newsGP weekly poll<br \/>\n    In the past two years, have you seen an increase in patients seeking medical certificates to take time off for depression, stress or anxiety due to workplace issues?<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; News &#13; The drug, which is sold as LEQEMBI, has been given the green light by the&hellip;\n","protected":false},"author":2,"featured_media":170160,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,63,137,490],"class_list":{"0":"post-170159","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-medication"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/170159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=170159"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/170159\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/170160"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=170159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=170159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=170159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}